Travere Therapeutics (TVTX) Stock Rallies Over 13% After Hours: Here's What Is Going On Travere Therapeut

Travere Therapeutics Inc.

(NASDAQ:TVTX) shares surged 13.44% to $63.55 in after-hours trading on Tuesday after the biopharmaceutical company posted second-quarter revenue that beat analyst expectations, even as earnings missed.

Revenue Beat Drives Momentum For the period ended Jun. 30, Travere reported total revenue of $169.58 million, exceeding analyst expectations of $159.32 million by 6.44%.

U.S. net product sales increased to $161.4 million, compared with $94.8 million a year earlier.

Sales of flagship drug FILSPARI reached $141.1 million, marking a 96% year-over-year increase.